Puma Biotechnology (PBYI) Retained Earnings (2010 - 2026)

Puma Biotechnology has reported Retained Earnings for 17 years, with the latest figure at -$1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 1.86% year-over-year to -$1.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.3 billion (up 1.86% YoY), and the FY2025 full-year result was -$1.3 billion, up 2.37% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.3 billion, roughly flat from -$1.3 billion in the prior quarter.
• The five-year high for Retained Earnings was -$26000.0 in Q1 2024, with the low at -$1.4 billion in Q1 2022.
• Historically, Retained Earnings has averaged -$1.3 billion across 5 years, with a median of -$1.3 billion in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 136078800.0% — and 2024, when it surged 100.0%.
• Puma Biotechnology's Retained Earnings stood at -$1.4 billion in 2022, then gained by 1.17% to -$1.3 billion in 2023, then gained by 2.25% to -$1.3 billion in 2024, then grew by 2.37% to -$1.3 billion in 2025, then slipped by 0.29% to -$1.3 billion in 2026.
• The last three Retained Earnings figures came in at -$1.3 billion (Q1 2026), -$1.3 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.